Please assess the completion status of the following clinical trial:

Trial Title: Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Biopsy confirmed advanced obstructing endobronchial non-small cell lung cancer~  * May have squamous cell carcinoma, adenocarcinoma, or large cell carcinoma histology~* Ineligible for or refused surgical resection~* Local endobronchial recurrence after prior surgical resection, radiotherapy, or chemotherapy allowed~* No evidence of tumor encasement of major pulmonary vessels on CT scan of the chest~PATIENT CHARACTERISTICS:~* Karnofsky performance status (PS) 50-100% OR ECOG PS 0-2~* WBC ≥ 4,000/mm³~* Platelet count ≥ 100,000/mm³~* Prothrombin time \< 1.5 times upper limit of normal (ULN)~* Total bilirubin ≤ 2.0 mg/dL~* Creatinine ≤ 2.0 mg/dL~* Alkaline phosphatase (hepatic) ≤ 3 times ULN~* SGOT ≤ 3 times ULN~* No contraindications for bronchoscopy~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after the completion of study treatment~* Patients with underlying lung disease must be judged (by the principal investigator) able to withstand mucous/debris formation at the site of treatment~* Patients who cannot breathe due to complete upper airway obstruction and who need emergency treatment to open the airway are not eligible~* No porphyria or hypersensitivity to porphyrin or porphyrin-like compounds~* No severe chronic obstructive pulmonary disease that, in the opinion of the investigator, would preclude multiple bronchoscopies~* No partial central airway obstruction from mucous/debris formation~* No high-grade upper airway obstruction of the trachea~PRIOR CONCURRENT THERAPY:~* Any type of prior therapy (e.g., chemotherapy or radiotherapy) for lung cancer allowed~* At least 4 weeks since prior and no concurrent chemotherapy or radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HPPH (Type: EXPERIMENTAL): Patients will receive 4 mg/m2 HPPH (given light exposure precautions) and approximately 2 days later be treated endoscopically with 150J/cm of 665 +-5nm light.

Based on this trial design, predict the completion outcome and termination type (if applicable).